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At many glutamatergic synapses, non-NMDA and NMDA receptors are co-2 
expressed postsynaptically. In the mammalian retina, glutamatergic rod bipolar cells 3 
are presynaptic to two rod amacrine cells (AII and A17) that constitute dyad 4 
postsynaptic partners opposite each presynaptic active zone. Whereas there is strong 5 
evidence for expression of non-NMDA receptors by both AII and A17 amacrines, the 6 
expression of NMDA receptors by the pre- and postsynaptic neurons in this 7 
microcircuit has not been resolved. Here, using patch-clamp recording from visually 8 
identified cells in rat retinal slices, we investigated the expression and functional 9 
properties of NMDA receptors in these cells with a combination of pharmacological 10 
and biophysical methods. Pressure application of NMDA did not evoke a response in 11 
rod bipolar cells, but for both AII and A17 amacrines, NMDA evoked responses that 12 
were blocked by a competitive antagonist (CPP) applied extracellularly and an open 13 
channel blocker (MK-801) applied intracellularly. NMDA-evoked responses also 14 
displayed strong Mg2+-dependent voltage block and were independent of gap 15 
junction coupling. With low-frequency application (60 s intervals), NMDA-evoked 16 
responses remained stable for up to 50 min, but with higher-frequency stimulation 17 
(10-20 s intervals) NMDA responses were strongly and reversibly suppressed. We 18 
observed strong potentiation when NMDA was applied in nominally Ca2+-free 19 
extracellular solution, potentially reflecting Ca2+-dependent NMDA receptor 20 
inactivation. These results indicate that expression of functional, i.e. conductance-21 
increasing, NMDA receptors is common to both AII and A17 amacrine cells and 22 
suggest that these receptors could play an important role for synaptic signaling, 23 
integration or plasticity in the rod pathway. 24 
 25 





The vast majority of excitatory synaptic transmission in the central nervous system is 28 
mediated by the amino acid glutamate (Hassel and Dingledine 2012). After synaptic 29 
release, glutamate diffuses across the synaptic cleft and binds to different types of 30 
receptors in the postsynaptic membrane. There are two main types of ionotropic 31 
glutamate receptors (iGluRs), termed N-methyl-D-aspartate (NMDA) receptors and 32 
non-NMDA receptors. These two types were originally defined based on their 33 
sensitivity to exogenous agonists, and non-NMDA receptors are further classified 34 
into AMPA and kainate receptors (reviewed by Hassel and Dingledine 2012; Smart 35 
and Paoletti 2012). More recently, molecular investigations have revealed that the 36 
pharmacologically defined types of receptors are composed of different subunits. 37 
NMDA receptors are heteromeric tetramers composed of two obligatory GluN1 38 
subunits and two accessory GluN2 subunits (GluN2A-D). AMPA receptors are 39 
homo- or heteromeric tetramers composed of GluA1-4 subunits and kainate 40 
receptors are homo- or heteromeric receptors composed of GluK1-5 subunits. At 41 
many glutamatergic synapses, the postsynaptic density contains both non-NMDA 42 
and NMDA receptors such that presynaptic release of glutamate activates both types 43 
of receptors, giving rise to a dual-component excitatory postsynaptic current (EPSC; 44 
Hassel and Dingledine 2012). At some synapses, however, either NMDA or non-45 
NMDA receptors seem to be missing and the EPSCs are mediated solely by one type 46 
of receptor, e.g. by NMDA receptors at "silent synapses" (Malinow et al. 2000) and 47 
non-NMDA receptors at climbing- and parallel-fiber synapses on Purkinje cells 48 
(Perkel et al. 1990). Because of their special functional properties, including high Ca2+ 49 
permeability, Mg2+-dependent voltage block at negative membrane potentials and 50 
slow kinetics (Traynelis et al. 2010), NMDA receptors and their role in synaptic 51 
signaling and plasticity have attracted intense investigation (Paoletti et al. 2013). 52 
 In the retina, glutamate is used as a neurotransmitter by both photoreceptors 53 
and bipolar cells, mediating input to horizontal cells and bipolar cells, and to 54 




cone pathway, the synaptic transmission between cone bipolar cells and ganglion 56 
cells can involve both non-NMDA and NMDA receptors, in both the ON and OFF 57 
pathways (Copenhagen et al. 1993) and NMDA receptors can contribute to contrast 58 
coding and temporal processing in ganglion cells (Manookin et al. 2010; Stafford et 59 
al. 2014). In the rod pathway, rod bipolar cells do not output their signals directly to 60 
ganglion cells (Strettoi et al. 1990, 1992). Instead, they contact AII amacrine cells 61 
which are presynaptic to ON-cone bipolar cells via electrical synapses and to OFF-62 
cone bipolar cells and ganglion cells via glycinergic synapses (Strettoi et al. 1992, 63 
1994). Through these connections, the AII amacrine is crucial for retinal signal 64 
processing not only under scotopic conditions (reviewed by Bloomfield and Dacheux 65 
2001), but also under mesopic and photopic conditions as well (Manookin et al. 2008; 66 
Münch et al. 2009). AMPA-type non-NMDA receptors make a substantial 67 
contribution to the EPSC evoked in AII amacrine cells by depolarization of 68 
presynaptic rod bipolar cells (Singer and Diamond 2003) and AII amacrine cells were 69 
thought not to express NMDA receptors (Boos et al. 1993). There is increasing 70 
evidence, however, from both physiological (Hartveit and Veruki 1997; Bloomfield 71 
and Xin 2000; Zhou and Dacheux 2004) and immunocytochemical (Kothmann et al. 72 
2012) investigations that AII amacrine cells do express NMDA receptors, suggesting 73 
that glutamatergic neurotransmission in these cells is more complex than originally 74 
believed. In addition to being presynaptic to AII amacrine cells, rod bipolar cells are 75 
also presynaptic to a second type of rod amacrine cell, termed AI or A17 (Kolb and 76 
Famiglietti 1974). A17 amacrines are wide-field amacrines that provide inhibitory 77 
GABAergic feedback to the rod bipolar cell (Nelson and Kolb 1985; Raviola and 78 
Dacheux 1987; Hartveit 1999; Chávez et al. 2006) and it has been suggested that they 79 
do not express NMDA receptors (Menger and Wässle 2000). At each specialized 80 
presynaptic release site (ribbon) of the axon terminal of a rod bipolar cell, two 81 
postsynaptic processes from an AII and an A17 amacrine cell collectively constitute a 82 
postsynaptic dyad (Kolb and Famiglietti 1974; Raviola and Dacheux 1987). On this 83 




expressed by AII amacrine cells and to investigate the potential expression of NMDA 85 
receptors by A17 amacrine cells. We also wanted to re-examine the presence of 86 
NMDA receptors in rod bipolar cells, for which there is conflicting evidence, 87 
suggesting both the presence (Karschin and Wässle 1990; Wenzel et al. 1997; Lo et al. 88 
1998) and absence of NMDA receptors on these cells (Hartveit 1996; Fletcher et al. 89 
2000). Here, we provide direct evidence that not only AII, but also A17 amacrine cells 90 
express functional (i.e. conductance-increasing) NMDA receptors, detected by 91 
recording whole-cell current responses evoked by application of NMDA. No such 92 
responses were observed in rod bipolar cells. Our results suggest that NMDA 93 
receptors could play a significant role in synaptic signaling or plasticity in the rod 94 
pathway.  95 
 96 
METHODS 97 
Retinal slice preparation and visual targeting of neurons 98 
General aspects of the methods have previously been described in detail (Veruki et 99 
al. 2003). Female albino rats (Wistar HanTac; 4-7 weeks postnatal) were deeply 100 
anaesthetized with isoflurane in oxygen and killed by cervical dislocation (procedure 101 
approved under the surveillance of the Norwegian Animal Research Authority). 102 
Vertical retinal slices were visualized using an Axioskop 2 FS (Zeiss) with a ×40 103 
water immersion objective and infrared differential interference contrast (IR-DIC) 104 
videomicroscopy.  105 
 106 
Solutions and drug application 107 
The standard extracellular perfusing solution was continuously bubbled with 95% O2 108 
- 5% CO2 and had the following composition (in mM): 125 NaCl, 25 NaHCO3, 2.5 109 
KCl, 2.5 CaCl2, 1 MgCl2, 10 glucose, pH 7.4. In some experiments, MgCl2 was omitted 110 
from the extracellular solution (with no replacement of divalent cations) to relieve 111 
the voltage-dependent block of NMDA receptors. For these experiments, cells were 112 




ensure a complete washout of the divalent cations. In a few experiments, both MgCl2 114 
and CaCl2 were omitted from the extracellular solution (with no replacement of 115 
divalent cations). Recording pipettes were filled with (mM): 125 potassium 116 
gluconate, 8 KCl, 5 Hepes, 1 CaCl2, 1 MgCl2, 5 EGTA, 4 Na2ATP, and 2 N-(2, 6-117 
dimethylphenylcarbamoylmethyl)triethylammonium bromide (QX-314; Tocris 118 
Bioscience, UK) or 125 potassium gluconate, 8 NaCl, 10 Hepes, 1 CaCl2, 5 EGTA, 4 119 
MgATP and 2 QX-314). pH was adjusted to 7.3 with KOH. For the acquisition of 120 
current-voltage (I-V) relationships, recording pipettes were filled with (mM): 125 121 
CsCH3SO3, 8 NaCl, 10 Hepes, 1 CaCl2, 5 EGTA, 15 tetraethylammonium chloride 122 
(TEA-Cl), 4 MgATP. pH was adjusted to 7.3 with CsOH. For most nucleated patch 123 
experiments cells were filled with (mM): 125 CsCl, 8 NaCl, 10 Hepes, 1 CaCl2, 5 124 
EGTA, 15 TEA-Cl, 4 MgATP. pH was adjusted to 7.3 with CsOH. For some nucleated 125 
patch experiments recording pipettes were filled with 125 potassium gluconate, 8 126 
NaCl, 10 Hepes, 1 CaCl2, 5 EGTA, 4 MgATP and 2 QX-314. pH was adjusted to 7.3 127 
with KOH. 128 
 For visualization of complete cellular morphologies with wide-field 129 
fluorescence microscopy after the recording, Lucifer yellow (1 mg/ml; Sigma-130 
Aldrich), Alexa Fluor 488 (50 µM; Invitrogen) or Alexa Fluor 594 (40 µM; Invitrogen) 131 
was included in the intracellular solutions. 132 
 For pressure application from glass pipettes, drugs were dissolved in a 133 
vehicle solution containing (mM): 145 NaCl, 2.5 KCl, 2.5 CaCl2, 1 MgCl2, 5 Na-Hepes, 134 
and 10 glucose. MgCl2 and CaCl2 were eliminated from this solution to match the 135 
bath solution as necessary. We used either a singlebarrel puffer pipette (similar in 136 
size and shape to the patch pipettes described below) filled with NMDA or a 137 
multibarrel puffer pipette with NMDA in one or more barrels and NMDA with the 138 
specific NMDA receptor antagonist (RS)-3-(2-carboxypiperazin-4-yl)-propyl-1-139 
phosphonic acid (CPP; 400 µM) in one or more separate barrels (seven barrels in 140 
total; for details, see Hartveit 1996). In all cases, the concentration of NMDA in the 141 




Dingledine 1988; Traynelis et al. 2010), either 10 µM glycine in the presence of 10 µM 143 
strychnine and 100 µM picrotoxin or 200 µM D-serine, was always included in the 144 
application pipette. For the nucleated patch experiments, individual barrels of the 145 
multibarrel pipettes were filled with 1 mM NMDA (with co-agonist), 1 mM GABA or 146 
1 mM glycine. For some experiments, 1 or 2 mM (5S,10R)-(+)-5-Methyl-10,11-147 
dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine maleate (MK-801; Tocris Bioscience) 148 
was added to the intracellular solution. Other neurotransmitter receptor antagonists 149 
and ion channel blockers were added directly to the extracellular solution at the 150 
following concentrations (supplied by Tocris Bioscience, unless otherwise indicated): 151 
1 µM strychnine (Research Biochemicals, Natick, MA, USA) to block glycine 152 
receptors; 10 µM (-)-bicuculline methochloride to block GABAA receptors; 50 µM 153 
(1,2,5,6-tetrahydropyridin-4-yl)methylphosphinic acid (TPMPA) to block GABAC 154 
receptors, 10 µM 6-cyano-7-nitroquinoxaline-2,3-dione (CNQX) to block non-NMDA 155 
receptors; 0.3 µM tetrodotoxin (TTX) to block voltage-gated Na+ channels; 100 µM 156 
2-[(2,6-dichloro-3-methylphenyl)amino]benzoic acid sodium salt (meclofenamic acid 157 
[MFA] sodium salt; Sigma-Aldrich). Solutions were either made up freshly for each 158 
experiment or were prepared from aliquots stored at -20°C and diluted to the final 159 
concentration on the day of the experiment.  160 
 161 
Electrophysiological recording and data acquisition 162 
Patch pipettes were pulled from thick-walled borosilicate glass (outer diameter, 1.5 163 
mm; inner diameter, 0.86 mm) to obtain an open-tip resistance that ranged from 5 to 164 
7 MΩ when filled with intracellular solution. Whole-cell voltage-clamp recordings 165 
were performed with an EPC9-dual amplifier (HEKA Elektronik, Lambrecht/Pfalz, 166 
Germany) and controlled with PatchMaster software (HEKA Elektronik). After 167 
establishing a GΩ-seal, currents caused by the recording electrode capacitance (fast 168 
capacitative current; "Cfast" function in PatchMaster) were automatically measured 169 
and neutralized by the amplifier. After breaking into the cell, currents caused by the 170 




PatchMaster) were partially neutralized by the amplifier. For whole cell recordings, 172 
series resistance (Rs) was monitored throughout the recording, at intervals of 1 173 
minute for most experiments, by applying a series of 20 mV hyperpolarizing voltage 174 
pulses (16 ms duration) after transiently disabling the Cslow neutralization circuitry of 175 
the amplifier. The charging transients were analyzed off-line by FitMaster software 176 
(HEKA Elektronik) by fitting the decay phase during the voltage pulse with a double 177 
exponential function and Rs was calculated from the amplitude of the voltage pulse 178 
and the peak current amplitude extrapolated to the onset of the pulse. Rs was not 179 
compensated. Cells with Rs > 40 MΩ were not included in the final material. 180 
 To establish a nucleated patch recording, the pipette was slowly withdrawn 181 
after establishing the whole-cell recording configuration, while continuous light 182 
suction (~50 mbar) was applied to the pipette. When a nucleated patch was 183 
successfully isolated, the reduced membrane capacitance resulted in capacitative 184 
current transients of the opposite polarity that were cancelled by re-adjustment of the 185 
Cslow neutralization circuitry. 186 
 The sampling interval was set to either 50 or 100 µs and before sampling, 187 
signals were low-pass filtered (analog 3- and 4-pole Bessel filters in series) with a 188 
corner frequency (-3 dB) of 4 kHz. All recordings were carried out at room 189 
temperature (22 - 25°C). The data acquisition software (PatchMaster) corrected all 190 
holding potentials for liquid junction potentials on-line. Theoretical liquid junction 191 
potentials were calculated with JPCalcW (Axon Instruments / Molecular Devices). 192 
 193 
Wide-field fluorescence microscopy 194 
All cells were inspected with wide-field fluorescence microscopy after recording. By 195 
visual observation through the microscope oculars, we inspected the morphology of 196 
each dye-filled neuron and its processes and the relationship between the branching 197 
pattern and the strata of the inner plexiform layer. For documentation, every dye-198 
filled neuron was sketched by hand. In addition, for some cells we acquired digital 199 




post-acquisition deconvolution to remove noise and increase resolution was 201 
performed as described previously (Castilho et al. 2015a). 202 
 203 
General data analysis 204 
Data were analyzed with FitMaster (HEKA Elektronik), IGOR Pro (WaveMetrics, 205 
Lake Oswego, OR, USA), and Excel (Microsoft, Redmond, WA, USA). The peak 206 
amplitude of NMDA-evoked currents was measured as the mean amplitude between 207 
two vertical cursors positioned close to the peak response as identified by eye. For 208 
acquisition of I-V relationships, the holding potential was incremented by 10 mV 209 
intervals. Data points of I-V relationships were connected by straight lines and 210 
reversal potentials (Erev) were determined by the intersection with the abscissa.  211 
 Data are presented as means ± SE (n = number of cells). Statistical analyses 212 
with comparisons between or within groups were performed using Student’s two-213 
tailed t test (paired or unpaired, as indicated). Differences were considered 214 
statistically significant at the P < 0.05 level. For illustration purposes, most raw data 215 
records were low-pass filtered (digital Gaussian filter, -3 dB at 500 Hz - 2 kHz). 216 
Fig. 1 near here 217 
 218 
RESULTS 219 
Targeting and identification of neurons in the rod bipolar-AII-A17 microcircuit in 220 
rat retinal slices 221 
The cell bodies of AII and A17 amacrine cells each have a characteristic shape and 222 
location at the border between the inner nuclear layer and the inner plexiform layer 223 
and as such, they can be readily targeted in an acute retinal slice preparation (Fig. 224 
1A). AII amacrine cells have cell bodies that span the border between the inner 225 
nuclear layer and the inner plexiform layer and are bi-stratified narrow-field 226 
amacrine cells whereas A17 amacrine cells have dome-shaped cell bodies with long, 227 
thin processes that carry distinct varicosities and terminate near the ganglion cell 228 




the inner nuclear layer, in close apposition to the outer plexiform layer (Fig. 1A). The 230 
intracellular solutions contained fluorescent dyes that diffused into the cells during 231 
recording and allowed unequivocal identification of the complete morphology after 232 
recording (Fig. 1B). For all three types of retinal neurons, NMDA and other drugs 233 
were applied from singlebarrel or multibarrel pipettes positioned close to the 234 
location of the neuron in the inner plexiform or the inner nuclear layer (Fig. 1A). 235 
Nucleated patches were isolated from AII and A17 amacrine cells by pulling the cell 236 
body out of the slice after establishing the whole-cell configuration and were used 237 
with drug application from multibarrel or singlebarrel puffer pipettes (Fig. 1C). For 238 
this study, we recorded from a total of 70 AII amacrine cells, 63 A17 amacrine cells, 239 
and 6 rod bipolar cells. 240 
Fig. 2 near here 241 
 242 
Both AII and A17 amacrine cells, but not rod bipolar cells, in rat retinal slices 243 
respond to application of NMDA 244 
AII and A17 amacrine cells form the dyad postsynaptic targets of ribbon synapses of 245 
glutamatergic rod bipolar cell axon terminals (Fig. 2A). There is evidence that NMDA 246 
receptors in glutamatergic synapses can have not only a conventional postsynaptic 247 
(including extrasynaptic) localization (Sheng and Kim 2012) to mediate synaptic 248 
transmission and control postsynaptic excitability, but also a presynaptic 249 
localization, potentially to control transmitter release (Engelman and MacDermott 250 
2004). Accordingly, NMDA receptors could be expressed by any or all of the three 251 
neuronal elements of this synaptic microcircuit. In principle, NMDA receptors could 252 
also be localized postsynaptically at rod bipolar cell dendrites in the outer plexiform 253 
layer where they receive glutamatergic input from rod photoreceptors (Massey and 254 
Maguire 1995).  255 
 We tested for the presence of functional, i.e. conductance-increasing, NMDA 256 
receptors in AII and A17 amacrine cells and in rod bipolar cells by pressure 257 




Mg2+-free solution in both the bath and the pipette (hereafter referred to as Mg2+-free 259 
solution). In both AII and A17 amacrine cells, NMDA evoked large inward currents 260 
at holding potentials of -60 mV and -70 mV, respectively (close to the resting 261 
potentials of the two cell types; Fig. 2B, C). The inward currents displayed relatively 262 
fast rise and decay times. All the AII and A17 amacrine cells tested under these 263 
conditions responded to NMDA. For AII amacrine cells, the average peak response 264 
was 64 ± 7 pA (n = 17, range 28 - 152 pA) and for A17 amacrine cells the average peak 265 
response was 85 ± 8 pA (n = 22, range 36 - 182 pA). 266 
 In contrast to the two types of rod amacrine cells, NMDA evoked no response 267 
in any of the rod bipolar cells tested (n = 6 cells). The traces illustrated for a rod 268 
bipolar cell in Fig. 2D, demonstrate how we examined two positions of the puffer 269 
pipette, with application directed either towards the axon terminal in the inner 270 
plexiform layer or towards the dendrites in the outer plexiform layer. In a typical 271 
recording, the first application of NMDA was performed within 1 - 3 min after 272 
breaking into the cell and establishing the whole-cell recording configuration. To 273 
minimize the likelihood that fast rundown of NMDA receptor channels (Horn and 274 
Korn 1992) could take place before the first application, we tested three rod bipolar 275 
cells with pressure application of NMDA within 20 s after breaking into the cells, but 276 
still did not observe any responses. In some recordings, we observed small sustained 277 
shifts in the current that were tightly synchronized to the duration of drug 278 
application. These shifts were not accompanied by changes in noise, as expected for 279 
channel gating (cf. Fig. 2B, C). When the pressure application of NMDA was 280 
preceded and followed by application of the vehicle solution (without agonist) from 281 
another barrel in the multibarrel complex (Fig. 2D), no shift in current was observed, 282 
suggesting that it was caused by a small difference in liquid junction potential 283 
between the bath solution and the solution in the puffer pipette. These results 284 
strongly suggest that rod bipolar cells do not express functional (conductance-285 
increasing) NMDA receptor channels. 286 





Functional properties of NMDA receptors in AII and A17 amacrine cells 289 
To examine whether the responses evoked by NMDA in AII and A17 amacrine cells 290 
were indeed mediated by NMDA receptors, we applied NMDA together with the 291 
specific NMDA receptor antagonist CPP (400 µM), with Mg2+-free solution in both 292 
the bath and the puffer pipette. For these experiments, we used a multibarrel pipette 293 
and first applied NMDA alone from one barrel, followed by co-application of NMDA 294 
and CPP from another barrel (the antagonist was included in the same barrel as 295 
NMDA). By directing the tip of the multibarrel pipette towards photoreceptors at the 296 
edge of the slice, we used pressure-evoked movements of photoreceptor outer 297 
segments as a visual control to verify that fluid was adequately ejected from all 298 
barrels used during the pharmacological testing. In the presence of CPP, the NMDA 299 
responses were completely blocked for both AII (n = 8 cells) and A17 (n = 5 cells) 300 
amacrine cells (Fig. 3A, B) and for both cell types the responses to NMDA recovered 301 
quickly following washout of CPP (Fig. 3A, B). 302 
Fig. 4 near here 303 
 These experiments strongly suggested that the responses to NMDA were 304 
mediated by NMDA receptors, but they do not by themselves demonstrate 305 
conclusively that the responses were mediated by receptors located on the cells that 306 
we recorded from. To rule out the possibility that the NMDA-evoked responses were 307 
mediated by transsynaptic network effects, we performed three sets of experiments. 308 
In the first set we applied an antagonist intracellularly to block NMDA-evoked 309 
responses, in the second set we verified the characteristic I-V relationship expected 310 
for NMDA receptor-mediated currents, and in the third set we tested for the 311 
presence of NMDA receptor-mediated responses after blocking gap junction-312 
mediated coupling pharmacologically. We first repeated the recordings with 313 
application of NMDA (in Mg2+-free extracellular solution) after including the NMDA 314 
receptor open-channel blocker MK-801 in the recording pipette solution (2 mM). In 315 




(approximately every 60 s), starting as soon as possible after establishing the whole-317 
cell recording condition. For AII amacrine cells (n = 8 cells), there was no response to 318 
NMDA, even during the very first application of NMDA which, for the cell 319 
illustrated in Fig. 4A, was obtained within 1 min after breaking into the cell. This is 320 
most likely explained by the small cell size and a relatively short diffusion distance 321 
from the tip of the pipette and cell body to the location of the NMDA receptors. As a 322 
positive control, AII amacrine cells in the same slices recorded without MK-801 323 
added to the intracellular solution displayed the expected inward currents evoked by 324 
application of NMDA (data not shown). 325 
 In contrast to AII amacrine cells, we typically observed a small, but clear, 326 
response in A17 amacrine cells recorded with MK-801 intracellularly when NMDA 327 
was applied within 1-2 min after establishing the whole-cell recording configuration. 328 
This is consistent with the larger length of the processes of these cells and the 329 
presumably correspondingly longer diffusion distance from the tip of the recording 330 
pipette and cell body to the location of the NMDA receptors. For the cell illustrated 331 
in Fig. 4B, the first NMDA-evoked response obtained after breaking into the cell 332 
displayed a peak amplitude of approximately 20 pA. With repeated application of 333 
NMDA (once every 60 s), we observed a gradual reduction of the response 334 
amplitude such that at approximately 4 min of recording, the response was almost 335 
completely abolished (Fig. 4B). For A17 amacrine cells recorded with MK-801 in the 336 
pipette solution, the average NMDA-evoked response was an inward current of 3 ± 337 
0.4 pA (n = 4 cells, range 2.6 to 4.2 pA) after approximately 4 min of recording. 338 
Fig. 5 near here 339 
 340 
Voltage-dependent block of NMDA receptors in AII and A17 amacrine cells 341 
NMDA receptors display a characteristic Mg2+-dependent voltage block (Nowak et 342 
al. 1984). To investigate this property for the NMDA receptors expressed by AII and 343 
A17 amacrine cells, we measured the I-V relationships of the NMDA-evoked 344 




recorded NMDA-evoked currents at a series of holding potentials between -80 mV 346 
and +60 mV. To block K+ conductances in the cells, including voltage-dependent 347 
conductances, the recording pipette solution contained Cs+ and TEA+ (see Methods). 348 
In the presence of extracellular Mg2+, the I-V curves for AII amacrines displayed a 349 
characteristic J-shape, with a negative slope conductance between -70 and -30 mV 350 
(Fig. 5A, C; filled circles), as is expected for NMDA receptors. When Mg2+ was omitted 351 
from the bath and puffer pipette solution, the NMDA-evoked responses were 352 
markedly enhanced at negative holding potentials (Fig. 5B) and the corresponding I-353 
V curves became considerably more linear (Fig. 5B, C; open circles). In the presence of 354 
Mg2+, the Erev for AII amacrine cells was 5.9 ± 3.6 mV (range -2.0 to 16.1 mV; n = 6 355 
cells) and in the absence of Mg2+ it was 4.8 ± 4.0 mV (range -6.1 to 18.0 mV; n = 5 356 
cells). There was no statistically significant difference between these values (P = 357 
0.8377; unpaired t test). 358 
 When A17 amacrine cells were tested with NMDA at different holding 359 
potentials, we noticed that for some cells (with normal extracellular Mg2+), the rise 360 
time was longer for responses at negative potentials between -80 and -30 mV (Fig. 361 
5D). Even with good voltage and space clamp control, such as when recording from 362 
round cells without processes, the inward current through NMDA receptor channels 363 
is not zero at these negative potentials. Because of the negative slope conductance, 364 
this current could rise to a regenerative depolarization with gradual release from the 365 
Mg2+-dependent voltage block when recording NMDA-evoked currents in A17 366 
amacrine cells with long thin processes and suboptimal conditions for good space 367 
clamp. This could contribute to the slow increase in the inward current at negative 368 
potentials observed for some A17 amacrines (Fig. 5D). 369 
 Because of these problems with A17 amacrine cells, we measured the current 370 
responses at the negative holding potentials at the same point in time where the peak 371 
responses at other holding potentials occurred. The I-V curve displayed a slight J-372 
shape with strong outward rectification (Fig. 5D, F; filled circles). Similar to the result 373 




Mg2+ in the extracellular solution, the responses were markedly enhanced at negative 375 
holding potentials (Fig. 5E), consistent with alleviation of a Mg2+-dependent voltage 376 
block. In this condition, the I-V curves were considerably more linear (Fig. 5F; open 377 
circles). In the presence of Mg2+, the Erev for A17 amacrine cells was 4.5 ± 6.2 mV 378 
(range -22 to 22 mV, n = 7 cells) and in the absence of Mg2+ it was 8.0 ± 4.8 mV (range 379 
-5.6 to 27 mV; n = 6 cells). The difference between these values was not statistically 380 
significant (P = 0.67749; unpaired t test). 381 
Fig. 6 near here 382 
 383 
Blocking gap junction-mediated coupling with MFA does not block NMDA-384 
evoked responses in AII or A17 amacrine cells 385 
We have previously demonstrated that MFA completely blocks the electrical 386 
synapses between AII amacrine cells and between AII amacrine cells and ON-cone 387 
bipolar cells (Veruki and Hartveit 2009). To exclude the possibility that the NMDA-388 
evoked responses observed in either AII or A17 amacrine cells were mediated 389 
indirectly by gap junction coupling to other cells, we repeated application of NMDA 390 
while we blocked gap junction coupling pharmacologically with MFA. NMDA (1 391 
mM, 1 s duration) was applied once every 60 s, starting immediately after 392 
establishing the whole-cell recording configuration when we also added MFA (100 393 
µM) to the extracellular solution to block electrical coupling. Because it takes 394 
approximately 30 min before the electrical coupling is completely blocked (Veruki 395 
and Hartveit 2009), the application of NMDA was continued for 40 - 45 min in the 396 
maintained presence of MFA. For the AII amacrine cell illustrated in Fig. 6A and the 397 
A17 amacrine cell illustrated in Fig. 6B, there was virtually no change in the 398 
responses over time. Similar results were seen for two other AII amacrine cells. These 399 
results strongly suggest that NMDA-evoked responses in AII or A17 amacrine cells 400 
were mediated by receptors on the cells themselves and not indirectly by gap 401 
junction-coupling to other neurons. 402 





Neurotransmitter receptors in nucleated patches from AII and A17 amacrine cells 405 
For a more detailed biophysical analysis of the functional properties of the NMDA 406 
responses expressed by AII and A17 amacrine cells, whole-cell recording and drug 407 
application from puffer pipettes is not an ideal method. The voltage control, 408 
including space-clamp, is suboptimal in recordings from both AII and A17 amacrine 409 
cells, both because of the presence of homologous and heterologous electrical 410 
coupling mediated by gap junctions (reviewed by Hartveit and Veruki 2012) and 411 
because of the presence of long and thin processes, particularly on the A17s (Fig. 1B). 412 
In addition, the speed of drug application obtainable with puffer pipettes and in vitro 413 
slices is too slow and variable for adequately measuring the kinetic properties of 414 
neurotransmitter receptors. On this background, we attempted a more detailed 415 
kinetic and biophysical investigation of the I-V properties of NMDA receptors 416 
expressed by AII and A17 amacrine cells by recording NMDA-evoked responses 417 
from nucleated patches. These are comparable to small round cells that offer a much 418 
better voltage and space clamp control and can be tested with faster drug 419 
application. In our laboratory, we have previously observed responses of 420 
conventional outside-out or nucleated patches from AII amacrine cells to application 421 
of several neurotransmitters and receptor agonists, including glutamate (Veruki et al. 422 
2003), kainate (Mørkve et al. 2002), AMPA (Mørkve et al. 2002; Castilho et al. 2015b), 423 
and glycine (Gill et al. 2006). 424 
 When we tested nucleated patches from AII and A17 amacrine cells, we 425 
applied NMDA (1 mM), GABA (1 mM) and glycine (1 mM) from separate barrels of 426 
a multibarrel pipette. For AII amacrine cells, 11/13 nucleated patches responded to 427 
GABA with robust currents and 13/13 patches responded to glycine with robust 428 
currents (Fig. 7A). We did not perform a detailed investigation of the I-V properties 429 
of the GABA and glycine receptors, but observed inward and outward currents at 430 
holding potentials of -60 and +20 mV, respectively (Fig. 7A), as expected for chloride-431 




with NMDA (at holding potential of -60 and +20 mV), 10/13 patches displayed no 433 
response and 3/13 patches responded with minimal currents (≤ 3 pA) and a small 434 
increase in membrane noise (Fig. 7A). 435 
Fig. 8 near here 436 
 For A17 amacrine cells, 15 nucleated patches were examined with drug 437 
application. All 15 patches were tested with GABA and responded with robust 438 
currents (Fig. 8A). Of the same 15 patches, 11 were tested with glycine and all 439 
responded with robust currents (Fig. 8A). When we tested these same patches with 440 
NMDA (in Mg2+-free extracellular solution and a holding potential of -60 mV), 12/15 441 
patches displayed no response and 3/15 patches responded with minimal currents (≤ 442 
3 pA) and an increase in membrane noise (Fig. 8A).  443 
 These results suggested that the general lack of NMDA-evoked responses in 444 
nucleated patches from AII and A17 amacrine cells reflects a lack of receptors and is 445 
not due to technical problems. As an additional control, we performed experiments 446 
where we first verified the presence of an NMDA-evoked response in the whole-cell 447 
configuration, isolated a nucleated patch from the same cell and tested it with 448 
application of NMDA. For AII amacrine cells tested in this way (n = 3), all displayed 449 
robust responses to NMDA in the whole-cell configuration, but only one cell 450 
responded after isolating a nucleated patch and the amplitude was < 3 pA (Fig. 7B). 451 
Similarly, when we tested A17 amacrine cells (n = 3), all displayed robust whole-cell 452 
responses to NMDA. When the corresponding nucleated patches were tested, all 453 
displayed a visible response to NMDA, but the responses were small (3.8 ± 0.8 pA, 454 
range 2.6 - 5.4 pA; Fig. 8B). Taken together, these experiments strongly suggested 455 
that there are very few NMDA receptors located in the cell membrane of the cell 456 
bodies of both AII and A17 amacrine cells, unfortunately precluding a rigorous 457 
kinetic and biophysical analysis. 458 





Agonist-dependent suppression of NMDA receptor-mediated responses in AII 461 
and A17 amacrine cells 462 
In a previous study of NMDA receptors in AII amacrine cells, we observed a 463 
relatively fast time- and agonist-dependent reduction of NMDA-evoked responses, 464 
with few cells maintaining responses after being stimulated with repeated 465 
application of NMDA for 10 - 15 minutes (Hartveit and Veruki 1997). Because the 466 
phenomenon seemed to depend on the duration of whole-cell recording, it was 467 
suggested that it was a consequence of receptor rundown, potentially reflecting the 468 
perturbation of neuromodulatory control. Such control is often mediated by 469 
phosphorylation of specific amino acids in receptor proteins, and there is strong 470 
evidence that NMDA receptors in different types of neurons are subject to such 471 
control (reviewed by Salter et al. 2009). There is also evidence, however, that NMDA 472 
receptors are influenced by more than one mechanism of desensitization (reviewed 473 
by Gibb 2010). On this background, we hypothesized that if the observed response 474 
reduction corresponded to classical rundown, it should be irreversible over time, 475 
whereas if it was caused e.g. by desensitization following agonist-dependent 476 
receptor activation, it should reverse, after reducing the frequency or intensity of 477 
stimulation. 478 
 We tested both AII and A17 amacrine cells by applying NMDA (1 s duration) 479 
at intervals of approximately 60 s for recording periods of 20 - 50 minutes (Fig. 9). 480 
The recordings were performed in Mg2+-free extracellular solution at negative 481 
holding potentials, near the resting membrane potentials of the cells. With this 482 
paradigm, we sometimes observed a sequential increase or decrease in response to 483 
the first 3 - 4 NMDA-evoked responses, but after that initial change in response, we 484 
observed no consistent change of the amplitude of NMDA-evoked responses in 485 
either AII (Fig. 9A) or A17 (Fig. 9B) amacrine cells within our recording periods. 486 
Fig. 10 near here 487 
 To investigate the conditions for the response reduction previously observed 488 




at more frequent intervals. For all cells, we first verified a stable baseline for 490 
approximately 5 min with an application interval of 60 s, before switching to more 491 
frequent applications of 10 - 15 s intervals. For the AII amacrine cell illustrated in Fig. 492 
10A, the response to low-frequency application of NMDA was relatively stable at 493 
around 250 pA. When the application interval was reduced from 60 s to 10 s, this led 494 
to an immediate reduction in the response amplitude that plateaued at around 170 495 
pA within 1 - 2 min, corresponding to a suppression of about 34%. In all cases, we 496 
made sure that the stimulation interval was sufficiently long for the membrane 497 
current to have recovered to the baseline level between subsequent applications of 498 
NMDA. After 5 min, the application interval was increased again to 60 s and the 499 
response amplitude increased over approximately 2 min, with an almost complete 500 
reversal of the suppression seen during the 10 s-interval application period (Fig. 501 
10A). During a second period of 10 s-interval applications, the suppression was 502 
slightly stronger (43%). When the application interval was increased to 60 s again, 503 
the responses recovered almost fully to the previous level (Fig. 10A). For the whole 504 
recording period, the series resistance varied slightly, but the change was gradual 505 
and unrelated to the temporally distinct suppression seen during the periods with 506 
increased stimulus frequency (Fig. 10A). For seven AII amacrine cells tested in this 507 
way, the NMDA-evoked response decreased in all cells, from 112 ± 29 pA (range 42 - 508 
254 pA) with an application interval of 60 s to 72 ± 24 pA (range 19 - 168 pA) with an 509 
application interval of 10 - 15 s, corresponding to an average decrease of 43 ± 9% (Fig. 510 
10B; P = 0.0067, paired t test). For five of the cells we were able to maintain the 511 
recordings sufficiently long that recovery could be observed (Fig. 10B). 512 
 The results for A17 amacrine cells were very similar to those for AII amacrine 513 
cells. For the A17 amacrine cell illustrated in Fig. 10C, the NMDA-evoked response 514 
was suppressed by about 60% when the application interval was reduced from 60 s 515 
to 12 s. The suppression was reversible and could be repeated (Fig. 10C). The series 516 
resistance increased slightly during the recording period, but was unrelated to the 517 




amacrine cells tested in this way, the NMDA-evoked response decreased in all cells, 519 
from 106 ± 19 pA (range 27 - 182 pA) with an application interval of 60 s to 57 ± 13 520 
pA (range 12 - 107 pA) with an application interval of 10 - 15 s, corresponding to an 521 
average decrease of 49 ± 3% (Fig. 10D; P = 0.00042, paired t test). The suppression 522 
reversed almost completely when the application interval was increased again (Fig. 523 
10D; one cell was lost before recovery was observed). 524 
Fig. 11 near here 525 
 526 
Reducing extracellular Ca2+ increases NMDA responses in AII and A17 amacrine 527 
cells 528 
One possible mechanism that can explain the response suppression observed when 529 
the frequency of application was increased is a negative feedback mediated by Ca2+ 530 
influx through the NMDA receptor channel itself (Rosenmund and Westbrook 1993). 531 
Influx of Ca2+, acting via calmodulin, constitutes a system for negative feedback of 532 
the Ca2+-permeable NMDA receptor channels (Ehlers et al. 1996; Zhang et al. 1998). 533 
To examine the potential Ca2+-sensitivity of NMDA receptors in AII and A17 534 
amacrine cells, we applied NMDA (1 s duration) at 60 s intervals and after a stable 535 
baseline had been established in Mg2+-free extracellular solution, we switched to a 536 
Mg2+- and Ca2+-free extracellular solution. For the AII amacrine cell illustrated in Fig. 537 
11A, the reduced extracellular Ca2+ immediately led to an increased response 538 
amplitude from a baseline response of approximately 250 pA to a level of 539 
approximately 430 pA, corresponding to an increase of 72%. When we switched back 540 
to the original extracellular solution and Ca2+ was washed back in, the amplitude of 541 
the NMDA-evoked responses returned to approximately 275 pA (Fig. 11A). For five 542 
AII amacrine cells tested in this way, the NMDA-evoked response increased in all 543 
cells, from 142 ± 33 pA (range 67 - 252 pA) in control (Mg2+-free) bath solution to 250 544 
± 52 pA (range 118 - 433 pA) in Mg2+- and Ca2+-free bath solution, corresponding to 545 




observed a reversal of the increase when we switched back to normal Ca2+, for the 547 
other two cells, the recording was lost before we could observe recovery. 548 
 When A17 amacrine cells were tested in the same way, the results were very 549 
similar to those observed for AII amacrine cells. For the A17 amacrine cell illustrated 550 
in Fig. 11C, the response increased by 110%. For five A17 amacrine cells, the NMDA-551 
evoked response increased in all cells, from 74 ± 22 pA (range 17 - 133) in control 552 
(Mg2+-free) bath solution to 118 ± 32 pA (range 36 - 201) in Mg2+- and Ca2+-free bath 553 
solution, corresponding to an average increase of 71 ± 11% (Fig. 11D; P = 0.0108, 554 
paired t test). Reversal was observed for three cells, with two cells lost before 555 
recovery could be observed. 556 
 557 
DISCUSSION  558 
In this study we have used a combination of physiological, pharmacological and 559 
biophysical methods to investigate the potential expression of functional (i.e. 560 
conductance-increasing) NMDA receptors by AII and A17 rod amacrine cells, as well 561 
as rod bipolar cells, in the rat retina. This information is important for understanding 562 
the neurotransmission between glutamatergic bipolar cells and rod amacrine cells, 563 
including possible mechanisms of synaptic integration and plasticity. The present 564 
results provide strong evidence that NMDA receptors are expressed by both AII and 565 
A17 amacrine cells, suggesting that these receptors can have a more important role in 566 
mediating glutamatergic signals to both types of amacrines than previously 567 
suspected. In the following, we will discuss the basis for our conclusion, discuss 568 
possible implications with respect to functional roles for NMDA receptors in these 569 
cells, and suggest how these questions might be investigated in future work. 570 
 For rod bipolar cells, we found no evidence for expression of functional 571 
(conductance-increasing) NMDA receptors. This is consistent with a previous report 572 
from our laboratory (Hartveit 1996), but we refined our investigation in the current 573 
study by increasing the spatial area over which the puffer pipette was positioned to 574 




rundown of receptor channels could not explain the absence of responses by 576 
minimizing the interval between breaking into the cells and applying NMDA. Earlier 577 
physiological evidence for functional NMDA receptors on rod bipolar cells is 578 
relatively weak, with no investigation of I-V properties and antagonist specificity 579 
(Karschin and Wässle 1990). The current results cannot by themselves explain 580 
previous evidence for immunoreactivity of rod bipolar cells for GluN1 (Lo et al. 581 
1998) and GluN2D (Wenzel et al. 1997) subunits. Assuming that the immunolabeling 582 
cannot be explained by antibody cross-reactivity, the physiological relevance of the 583 
expression is questioned by the absence of any evidence for a conductance that can 584 
be activated by NMDA. 585 
 586 
Evidence for expression of NMDA receptors by AII and A17 amacrine cells 587 
Whether a specific type of neuron expresses a specific type of neurotransmitter 588 
receptor is apparently a simple and well-defined question, but strong and 589 
unequivocal evidence can often be difficult to obtain. First, the type of neuron needs 590 
to be well-defined and it is necessary to be able to uniquely identify and target 591 
individual neurons of the right type. In our case, both AII and A17 amacrine cells are 592 
well-defined types of amacrine cells with unique cellular morphologies (reviewed by 593 
Masland 2001) and reasonably well-characterized synaptic inputs and outputs 594 
(reviewed by Hartveit and Veruki 2012). In addition, as demonstrated in this study 595 
and several previous studies, both from our laboratory (Veruki and Hartveit 2002a, 596 
2002b, 2009; Mørkve et al. 2002; Veruki et al. 2003; Castilho et al. 2015a) as well as 597 
from others (e.g. Boos et al. 1993; Menger and Wässle 2000; Singer and Diamond 598 
2003; Eggers and Lukasiewicz 2006; Grimes et al. 2010, 2014), both AII and A17 599 
amacrine cells can be reliably identified and targeted in the acute retinal slice 600 
preparation (Fig. 1A). The morphology observed with IR video microscopy and 601 
contrast enhancement techniques (e.g. DIC) is not sufficient, however, for a secure 602 
identification. Therefore, all cells we recorded from were also examined with 603 




solution, allowing us to visually inspect the complete neuronal morphology as 605 
preserved in the acute retinal slice preparation (Fig. 1B).  606 
 In our physiological experiments, we stimulated NMDA receptors by puffer 607 
pipette application of the specific agonist NMDA. Binding of agonist to the receptor 608 
triggers channel opening and the resulting current can be recorded as an inward 609 
current. When measuring such currents, a series of control experiments are necessary 610 
before one can conclude that specific receptors are expressed by the neuron being 611 
recorded. First, it is necessary to demonstrate that the response is mediated by 612 
specific receptors. Second, it is necessary to verify that the activated receptors display 613 
functional properties that are characteristic for the specific receptor type. Third, it is 614 
important to provide evidence that the responses are mediated by receptors 615 
expressed by the cells recorded from, as opposed to being mediated by specific 616 
receptors expressed by other types of neurons and conveyed to the cells recorded 617 
from through synaptic network mechanisms. 618 
 With respect to pharmacological specificity, two sets of experiments argue for 619 
the involvement of specific NMDA receptors. First, the responses evoked by 620 
application of NMDA could be completely blocked by CPP, a competitive antagonist 621 
that is specific for NMDA receptors (Davies et al. 1986). Second, the responses were 622 
also abolished (for AII amacrines) and strongly suppressed (for A17 amacrines) 623 
when the noncompetitive NMDA receptor antagonist and open channel blocker 624 
MK-801 (Wong et al. 1986; Huettner and Bean 1988) was applied intracellularly. The 625 
difference between AII and A17 amacrine cells is most likely due to lower 626 
concentrations of MK-801 that reach the location of the receptors in A17 amacrines 627 
because these cells have very long and thin processes that restrict and delay spread 628 
by diffusion intracellularly. 629 
 With respect to functional properties, we demonstrated that the responses 630 
evoked by NMDA in whole-cell recordings from both AII and A17 amacrine cells 631 
displayed I-V properties that are unique for NMDA receptors. First, the I-V curves 632 




mV (Nowak et al. 1984). From detailed biophysical investigations, we know that this 634 
reflects a Mg2+-dependent voltage block of the ion channel associated with the 635 
NMDA receptor complex (Nowak et al. 1984). Second, when Mg2+ was removed from 636 
the extracellular solution, the voltage block disappeared and the shape of the I-V 637 
curves became more linear for both AII and A17 amacrine cells. For both AII and A17 638 
amacrine cells, the Erev of the NMDA-evoked current was close to 0 mV, consistent 639 
with activation of non-selective cation channels. 640 
 The I-V relationship of the NMDA response and the results with MK-801 also 641 
provide strong evidence that the NMDA receptors must be localized on the AII and 642 
A17 amacrine cells themselves. First, if the NMDA receptors were not localized on 643 
the cell from which the whole-cell recording was performed, it is unlikely that 644 
changing the holding potential, as was done in the experiments investigating I-V 645 
properties, would have changed the driving force to generate the observed I-V 646 
curves. For example, AII amacrine cells are coupled to ON-cone bipolar cells via 647 
electrical synapses mediated by gap junctions (Strettoi et al. 1992, 1994; Veruki and 648 
Hartveit 2002b) and when recording from ON-cone bipolar cells that do not express 649 
non-NMDA receptors, it is possible to measure responses evoked by non-NMDA 650 
receptor agonists, presumably mediated by activating receptors on AII amacrines 651 
(Hartveit 1997). Importantly, however, it is not possible to reverse the direction of the 652 
evoked currents, presumably because the resistance of the electrical synapses is too 653 
high to adequately control the voltage at the location of the ion channels being 654 
activated. 655 
 Second, because the NMDA receptor antagonist MK-801 blocked responses 656 
mediated by NMDA in both AII and A17 amacrine cells after being applied 657 
intracellularly, the most likely interpretation is that the responses were mediated by 658 
receptors located in the AII and A17 amacrine cells themselves, where MK-801 could 659 
diffuse to the receptors within the processes of these cells. It has to be taken into 660 
account, however, that with puffer pipette application of drugs to cells in in vitro 661 




not know the extent to which pressure-applied NMDA, directed at a specific cell, 663 
could also reach neighboring cells. Whereas MK-801 strongly suppressed NMDA-664 
evoked responses in both AII and A17 amacrine cells, we cannot exclude the 665 
possibility that MK-801 could diffuse across gap junctions that couple these cells to 666 
other neurons. On the other hand, current knowledge of the possibilities available for 667 
such coupling suggests that if such difusion of MK-801 should occur, it would not 668 
change the conclusion. For homologous coupling, i.e. gap junctions that couple AII 669 
amacrines to other AII amacrines (Strettoi et al. 1992; Veruki and Hartveit 2002a) and 670 
A17 amacrines to other A17 amacrines (Li et al. 2002; Grimes et al. 2014), any 671 
indirectly mediated NMDA receptor-mediated responses blocked by diffusion of 672 
MK-801 would originate from NMDA receptors in cells of the same type as recorded 673 
from. There is also the possibility that heterologous coupling between AII amacrine 674 
cells and ON-cone bipolar cells (Strettoi et al. 1992, 1994; Veruki and Hartveit 2002b) 675 
could mediate indirect responses, but existing evidence suggests that ON-cone 676 
bipolar cells do not express NMDA receptors (Hartveit 1997). Irrespective of the 677 
possibilities for indirect effects mediated via gap junction coupling, NMDA-evoked 678 
responses in both AII and A17 amacrine cells were resistant to the gap junction 679 
blocker MFA, strongly suggesting that the NMDA-evoked responses of these 680 
neurons were mediated by receptors expressed on the cells themselves. 681 
 Because neurons are branched structures with dendritic processes that can 682 
extend over hundreds of µm, it can be challenging and even impossible to obtain the 683 
degree of experimental control that is required for rigorous biophysical 684 
investigations of the functional properties of ion channels and receptors expressed 685 
along these processes. Whereas investigating the functional properties in isolated 686 
membrane patches, either conventional outside-out patches or nucleated patches, can 687 
to a large extent compensate for this (e.g. Hartveit and Veruki 2007), we were 688 
unfortunately unsuccessful in using this approach for more detailed investigations of 689 
the NMDA receptors expressed by AII and A17 amacrine cells. Apart from the apical 690 




excising outside-out patches. Nucleated patches can be isolated for both types of 692 
cells, but the NMDA-evoked responses were unfortunately too small and infrequent 693 
to allow adequate analysis. As a control that the lack of responses was not due to 694 
technical or methodological problems, we performed experiments where we applied 695 
the receptor ligands GABA and glycine to the same patches. These ligands evoked 696 
robust responses, confirming previous results for non-NMDA-type glutamate 697 
receptors (Mørkve et al. 2002; Veruki et al. 2003) and glycine receptors (Gill et al. 698 
2006) at the cell bodies of AII amacrine cells and indicating that the lack of responses 699 
obtained with NMDA was due to lack of the receptors themselves and not technical 700 
problems. The results for A17 amacrine cells suggest that functional properties of 701 
GABA and glycine receptors in these cells can be fruitfully investigated by this 702 
technique in future studies. 703 
 704 
Activity-dependent suppression of NMDA receptors in AII and A17 amacrine cells 705 
The reduction of NMDA-evoked responses in AII amacrine cells previously observed 706 
in our laboratory was interpreted as reflecting rundown (Hartveit and Veruki 1997). 707 
Rundown is a phenomenon observed for several types of receptors and ion channels 708 
and is considered to be a consequence of washout of the intracellular environment 709 
after establishing the whole-cell recording configuration (Horn and Korn 1992). 710 
Accordingly, the response reduction will occur simply as a function of time. This 711 
kind of mechanism is not consistent with the observations made in the current study. 712 
First, by restricting the frequency of application of NMDA to once every 60 s, the 713 
response was very stable for recording periods up to 25 - 50 min. The ability to 714 
maintain stable NMDA responses for such extended time periods did not depend on 715 
recording with high series resistance or other measures (e.g. perforated patch) to 716 
slow or prevent rundown. This suggests that the NMDA receptors in AII and A17 717 
amacrine cells are not particularly susceptible to rundown as such. 718 
 Second, by increasing the frequency of stimulation, corresponding to 719 




that reversed quickly after reducing the frequency of stimulation. Thus, our results 721 
suggest that the suppression of NMDA-evoked responses is an expression of an 722 
activity-dependent feedback mechanism. Although our results do not provide a 723 
mechanistic explanation, a possible explanation is Ca2+-dependent inactivation which 724 
constitutes one form of desensitization of NMDA receptors (for review, see Gibb 725 
2010) and has been observed for both native receptors and receptors in heterologous 726 
expression systems (Rosenmund and Westbrook 1993; Ehlers et al. 1996). This is 727 
supported by our observation of an increased response to NMDA in nominally Ca2+-728 
free extracellular solution for both AII and A17 amacrine cells. Although we have not 729 
directly verified Ca2+ influx through NMDA receptor channels in either AII or A17 730 
amacrine cells, NMDA receptors have been found to be the predominant source of 731 
Ca2+ signals in several types of neurons, both because of their high Ca2+ permeability 732 
and their slow kinetics (reviewed by Higley and Sabatini 2012). Further work is 733 
required to decide if this mechanism is operative for the NMDA receptors in AII and 734 
A17 amacrine cells and whether it plays a specific functional role for signal 735 
processing in these cells. 736 
 737 
Functional role of NMDA receptors in AII and A17 amacrine cells 738 
Despite what we believe is strong evidence for the expression of NMDA receptors by 739 
both AII and A17 amacrine cells, very little is known with respect to any functional 740 
role of these receptors for the signal processing that takes place in these cells. For AII 741 
amacrine cells, there is no evidence for an NMDA receptor-mediated component in 742 
the response evoked by depolarization of a presynaptic rod bipolar cell (Singer and 743 
Diamond 2003). To our knowledge, nothing is known with respect to the receptors 744 
mediating input from (some) OFF-cone bipolar cells to the lobular appendages of AII 745 
amacrine cells (Strettoi et al. 1992, 1994; Veruki et al. 2003). Immunocytochemical 746 
investigations at the ultrastructural level have not found evidence for NMDA 747 
receptors postsynaptic to rod bipolar cells (Fletcher et al. 2000), but there is evidence 748 




arboreal dendrites of AII amacrine cells (Kothmann et al. 2012). Interestingly, GluN1 750 
was colocalized with Cx36 that mediates gap junction coupling between AII 751 
amacrine cells and Kothmann et al. (2012) found evidence that NMDA receptors 752 
could be involved in regulating the strength of coupling between these cells. 753 
 For A17 amacrine cells, the reciprocal feedback inhibition that is triggered by 754 
depolarization and glutamate release from rod bipolar cells is not blocked in the 755 
presence of the NMDA receptor antagonist CPP (Hartveit 1999), although similar 756 
experiments with Mb1 bipolar cells in the goldfish retina suggest that NMDA 757 
receptors can contribute to the feedforward excitation of inhibitory amacrine cells, at 758 
least under some conditions (Vigh and von Gersdorff 2005). Rod bipolar cells seem to 759 
constitute the only source of glutamatergic, bipolar cell input to A17 amacrine cells 760 
(Nelson and Kolb 1985). If NMDA receptors in the A17 are not localized postsynaptic 761 
to rod bipolars, the only alternative left open would seem to be an extrasynaptic 762 
location.  763 
 As expression of NMDA receptors now seems to be a property that is shared 764 
by both types of amacrine cells postsynaptic to rod bipolar cells, it is possible that 765 
information about the subunit composition of the NMDA receptors expressed by the 766 
two cell types can provide valuable information. For many regions and cell types in 767 
the CNS, it is known that the NMDA receptor subunit expression and composition 768 
displays striking variation, not only between regions, but also between cell types and 769 
even between different subcellular regions within single neurons (Nusser 2008; 770 
Paoletti et al. 2013). From in situ hybridization studies, we know that the GluN2A, 771 
GluN2B, and GluN2C subunits of the NMDA receptor are expressed in the rat retina, 772 
with considerable heterogeneity among amacrine cells in the INL, but the resolution 773 
is not sufficient to decide the specific identity of the various cells (Brandstätter et al. 774 
1994). This, together with the mechanisms and conditions for activation of NMDA 775 
receptors on AII and A17 amacrine cells, remain important questions for future 776 
investigations. NMDA receptors might contribute directly to signaling in these 777 




other ion channels that are more directly responsible for signal processing and 779 
integration.  780 
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FIGURE LEGENDS 967 
Fig. 1. Identification of rod amacrine cells (AII and A17) and rod bipolar cells in the 968 
rat retinal slice preparation. A: left, infrared differential interference contrast (IR-DIC) 969 
videomicrograph of an A17 amacrine cell in a retinal slice. Whole-cell recording with 970 
upper pipette (located at cell body). Lower pipette for drug application. Middle, IR-971 
DIC videomicrograph of an AII amacrine cell in a retinal slice. Whole-cell recording 972 
with upper pipette (located at cell body). Lower pipette for drug application. Right, 973 
IR-DIC videomicrograph of a rod bipolar cell in a retinal slice. Whole-cell recording 974 
with pipette located at cell body. B: maximum intensity projections (along Z-axis) 975 
generated from wide-field fluorescence image stacks (after deconvolution) for cells 976 
recorded in retinal slices and filled with Alexa Fluor 594 via patch pipettes: A17 977 
amacrine cell (left), AII amacrine cell (middle), and rod bipolar cell (right). C: left, 978 
IR-DIC videomicrograph of a nucleated patch pulled from an AII amacrine cell in the 979 
retinal slice and a multibarrel pipette for drug application. Right: IR-DIC 980 
videomicrograph of a nucleated patch pulled from an AII amacrine cell in the retinal 981 
slice and a single pipette for drug application. Scale bars: A-C, 10 µm. 982 
 983 
Fig. 2. AII and A17 amacrine cells, but not rod bipolar cells, express functional 984 
(conductance-increasing) NMDA receptors. A: schematic diagram of retinal 985 
microcircuit consisting of a rod bipolar cell (RBC) and AII and A17 amacrine cells. 986 
Arrows indicate direction and sign of synaptic transmission between the cells: 987 
feedforward glutamatergic transmission from RBCs to AII and A17 amacrines (solid 988 
arrows) and feedback GABAergic transmission from A17 amacrine to RBC (open 989 
arrow). B: current activated in an AII amacrine cell (Vhold = -60 mV) by application of 990 
NMDA (1 mM, 1 s) from a puffer pipette. Except where indicated, NMDA was 991 
always applied together with the co-agonist D-serine (200 µM). Here and later, 992 
recording configuration indicated by the schematic figure (right). In this and 993 
subsequent figures, the duration of drug application is indicated by the horizontal 994 




in nominally Mg2+-free extracellular solution (both in the bath and in the drug 996 
pipette). C: current activated in an A17 amacrine cell (Vhold = -60 mV) by application 997 
(1 s) of NMDA (1 mM) from a puffer pipette. D, No current activated in a rod bipolar 998 
cell (Vhold = -60 mV) by application of NMDA (1 mM, 1 s) from a multibarrel puffer 999 
pipette. The two traces correspond to application directed towards the soma-1000 
dendritic region (1) and the axon terminal region (2), obtained by moving the 1001 
multibarrel pipette as indicated in the schematic figure (right). To avoid confounding 1002 
effects caused by application of the vehicle solution itself, application of NMDA was 1003 
preceded and followed by application of vehicle solution without agonist from a 1004 
different barrel of the multibarrel pipette (broken horizontal lines). The extracellular 1005 
solution contained strychnine, bicuculline, TPMPA, CNQX, and TTX (see Methods). 1006 
 1007 
Fig. 3. AII and A17 amacrine cells express NMDA receptors blocked by the specific 1008 
antagonist CPP. A: currents activated in an AII amacrine cell (Vhold = -60 mV) by 1009 
application (1.5 s) of NMDA (1 mM) from a multibarrel puffer pipette. Top trace: 1010 
response evoked by NMDA in the control condition. Middle trace: no response to 1011 
NMDA when co-applied with CPP (400 µM) in the same pipette barrel. Bottom trace: 1012 
recovery of response to NMDA after washing out CPP. Here and in B, the 1013 
extracellular solution contained strychnine, bicuculline, CNQX, and TTX (see 1014 
Methods). B: currents activated in an A17 amacrine cell (Vhold = -70 mV) by 1015 
application (1.5 s) of NMDA (1 mM) from a multibarrel puffer pipette. Top trace: 1016 
response evoked by NMDA in the control condition. Middle trace: no response to 1017 
NMDA when co-applied with CPP (400 µM) in the same pipette barrel. Bottom trace: 1018 
recovery of response to NMDA after washing out CPP. 1019 
 1020 
Fig. 4. AII and A17 amacrine cells express NMDA receptors blocked by intracellular 1021 
application of the specific noncompetitive antagonist (open-channel blocker) MK-1022 
801. A: currents recorded in an AII amacrine cell (Vhold = -60 mV) with application (1 1023 




solution in the recording pipette. Here and in B, time points at the right of each trace 1025 
indicate the approximate time after breaking into the cell and establishing the whole-1026 
cell recording configuration. Notice lack of response to NMDA even during the first 1027 
application. Here and in B, the extracellular solution contained strychnine, 1028 
bicuculline, CNQX, and TTX (see Methods). B: currents recorded in an A17 amacrine 1029 
cell (Vhold = -70 mV) with application (1 s) of NMDA (1 mM) from a puffer pipette. 1030 
MK-801 (2 mM) added to the intracellular solution in the recording pipette. Notice 1031 
response to NMDA during the first application and gradual reduction of response 1032 
amplitude during subsequent applications reflecting increasing block of NMDA 1033 
receptors by MK-801. 1034 
 1035 
Fig. 5. Current-voltage (I-V) relationships of NMDA-evoked whole-cell currents 1036 
responses in AII and A17 amacrine cells. A: NMDA-evoked (1 mM, 1 s) responses in 1037 
an AII amacrine cell, normal (1 mM) Mg2+ extracellularly. Here and in subsequent 1038 
figures, voltages next to the current traces indicate holding potential of cell (-80 to 1039 
+60 mV) and circle below traces indicates position of time window for averaging the 1040 
response amplitude. Here and in B, the extracellular solution contained CNQX and 1041 
TTX (see Methods). B: NMDA-evoked (1 mM, 1 s) responses in an AII amacrine cell, 1042 
nominally Mg2+-free extracellular solution. Notice larger NMDA-evoked responses at 1043 
negative holding potentials compared to A. C: left, I-V relationship for NMDA-1044 
evoked peak responses in six AII amacrines in normal Mg2+ extracellularly (as in A, 1045 
filled circles) and five AII amacrines in nominally Mg2+-free extracellular solution (as 1046 
in B, open circles). Here and in subsequent figures, the NMDA-evoked current at 1047 
each holding potential is plotted as mean ± SE; n = 4 - 6 cells for each data point). 1048 
Data points connected by straight lines. Right, I-V relationship for NMDA-evoked 1049 
peak responses, same data as in left panel, but data points normalized to the current 1050 
at +40 mV. Data points connected by straight lines. D: NMDA-evoked (1 mM, 1 s) 1051 
responses in an A17 amacrine cell, normal (1 mM) Mg2+ extracellularly. Here and in 1052 




Methods). E: NMDA-evoked (1 mM, 1.5 s) responses in an A17 amacrine cell, 1054 
nominally Mg2+-free extracellular solution. Notice larger NMDA-evoked responses at 1055 
negative holding potentials compared to D. F: left, I-V relationship for NMDA-1056 
evoked peak responses in seven A17 amacrines in normal Mg2+ extracellularly (as in 1057 
D, filled circles) and six A17 amacrines in nominally Mg2+-free extracellular solution 1058 
(as in E, open circles; n = 4 -7 cells for each data point). Data points connected by 1059 
straight lines. Right, I-V relationship for NMDA-evoked peak responses, same data as 1060 
in left panel, but with data points normalized to the current at +40 mV. Data points 1061 
connected by straight lines. 1062 
 1063 
Fig. 6. Blocking gap junction coupling pharmacologically with meclofenamic acid 1064 
(MFA) does not block NMDA-evoked responses in AII or A17 amacrine cells. A: 1065 
currents activated in an AII amacrine cell (Vhold = -60 mV) by application of NMDA (1 1066 
mM, 1 s) from a puffer pipette at 7 (top), 27 (middle), and 45 (bottom) min of whole-1067 
cell recording with MFA (100 µM) in the extracellular solution. B: currents activated 1068 
in an A17 amacrine cell (Vhold = -60 mV) by application of NMDA (1 mM, 1 s) from a 1069 
puffer pipette at 7 (top), 23 (middle), and 38 (bottom) min of whole-cell recording with 1070 
MFA (100 µM) in the extracellular solution. NMDA was applied every 60 s (A, B). 1071 
Notice how NMDA-evoked responses are maintained in the presence of MFA (A, B). 1072 
 1073 
Fig. 7. Nucleated patches from AII amacrine cells do not respond to NMDA. A: no 1074 
response of nucleated patch to application of NMDA (1 mM, 3 s; upper right traces) 1075 
at -60 or +20 mV (as indicated), normal (1 mM) Mg2+ extracellularly. Here and in B, 1076 
NMDA was applied together with the co-agonist glycine (10 µM) and strychnine (10 1077 
µM) and picrotoxin (100 µM) to block conventional glycine receptors. Robust 1078 
responses of same nucleated patch to application of glycine (1 mM, 100 ms; lower left 1079 
traces) and GABA (1 mM, 500 ms; lower right traces) at -60 mV (inward currents) 1080 
and +20 mV (outward currents). B: clear response to NMDA of AII amacrine cell 1081 




recording in retinal slice (upper right trace; recording configuration indicated in 1083 
upper left panel), but no response when tested with NMDA after pulling nucleated 1084 
patch (lower right trace; recording configuration indicated in lower left panel). 1085 
 1086 
Fig. 8. Nucleated patches from A17 amacrine cells show no or only minimal response 1087 
to NMDA. A: no response of nucleated patch to application of NMDA (1 mM, 1 s; 1088 
upper right traces) at -60 or +20 mV (as indicated). Robust responses of same 1089 
nucleated patch to application of glycine (1 mM, 500 ms; lower left traces) and GABA 1090 
(1 mM, 500 ms; lower right traces) at -60 mV (inward currents) and +20 mV (outward 1091 
currents). B: clear response to NMDA of A17 amacrine cell (voltage clamped at -60 1092 
mV) during whole-cell recording in retinal slice (upper right trace; recording 1093 
configuration indicated in upper left panel), but only minimal response with increase 1094 
in membrane noise when tested with NMDA after pulling nucleated patch (lower 1095 
right trace; recording configuration indicated in lower left panel). 1096 
 1097 
Fig. 9. NMDA-evoked responses in AII and A17 amacrine cells display temporal 1098 
stability without rundown. A: top, time series of peak response amplitude of an AII 1099 
amacrine cell (Vhold = -60 mV) to repeated application of NMDA (1 mM, 1 s duration, 1100 
60 s interval) during 50 min. Notice stability of response amplitude. Bottom, time 1101 
series of peak response amplitude of AII amacrine cells (as in top panel; n = 4 cells) to 1102 
repeated application of NMDA (1 mM, 1 s). Here and in B, time "0" indicates the time 1103 
of breaking into the cell and establishing the whole-cell recording configuration, data 1104 
points plotted as means ± SE and normalized to the current evoked by the first 1105 
application for each cell (n = 1 - 4 cells for each data point, depending on duration of 1106 
recording). B: top, time series of peak response amplitude of an A17 amacrine cell 1107 
(Vhold = -70 mV) to repeated application of NMDA (1 mM, 1 s duration, 60 s interval) 1108 
during 26 min. Notice stability of response amplitude. Bottom, time series of peak 1109 




application of NMDA (1 mM, 1 s; n = 3 - 6 cells for each data point, depending on 1111 
duration of recording). 1112 
 1113 
Fig. 10. Frequency-dependent suppression of NMDA-evoked responses in AII and 1114 
A17 amacrine cells. A: top, time series of peak response amplitude of an AII amacrine 1115 
cell (Vhold = -60 mV) to repeated application of NMDA (1 mM, 1 s duration). For the 1116 
cell illustrated, testing started after about 20 min of recording. Interval between 1117 
pulses: 60 s (22 - 29 min), 10 s (29 - 33 min), 60 s (34 - 43 min), 10 s (43 - 46 min), and 1118 
60 s (47 - 56 min). Notice response reduction during higher-frequency application of 1119 
NMDA. Numbers (1, 2, and 3) correspond to raw data traces (bottom) displaying 1120 
responses evoked by NMDA application during lower- (1, 3) and higher-frequency 1121 
(2) stimulation periods. Here and in C, time "0" indicates the time of breaking into the 1122 
cell and establishing the whole-cell recording configuration. Middle, time series of 1123 
corresponding estimates of series resistance (Rs) for whole-cell recording in top 1124 
panel. Rs estimate updated between each application of NMDA. Notice relative 1125 
stability of Rs. B: peak amplitude of NMDA-evoked responses (here and below, bars 1126 
represent means ± SE) in AII amacrine cells (n = 7 cells) in control condition with 60 s 1127 
intervals between NMDA-applications (Control; left bar), during higher-frequency 1128 
stimulation with 10 - 15 s intervals between NMDA-applications (High-freq.; middle 1129 
bar), and after return to the control condition (Recovery; right bar). Here and later, 1130 
data points for the same cell are connected by lines and the results from statistical 1131 
comparisons between averages are indicated by a single asterisk (statistically 1132 
significant difference; P < 0.05). C: top, time series of peak response amplitude of an 1133 
A17 amacrine cell (Vhold = -70 mV) to repeated application of NMDA (1 mM, 1 s 1134 
duration). Interval between pulses: 60 s (3 - 9 min), 12 s (9 - 15 min), 60 s (17 - 25 min), 1135 
and 12 s (26 - 32 min). Notice response reduction during higher-frequency 1136 
application of NMDA. Numbers (1, 2, and 3) correspond to raw data traces (bottom) 1137 
displaying responses evoked by NMDA application during lower- (1, 3) and higher-1138 




Rs for whole-cell recording in top panel. Rs estimate updated between each 1140 
application of NMDA. Notice relative stability of Rs. D: peak amplitude of NMDA-1141 
evoked responses in A17 amascrine cells (n = 8 cells) in control condition with 60 s 1142 
intervals between NMDA-applications (Control; left bar), during higher-frequency 1143 
stimulation with 10 - 15 s intervals between NMDA-applications (High-freq.; middle 1144 
bar), and after return to the control condition (Recovery; right bar). 1145 
 1146 
Fig. 11. Ca2+-dependent suppression of NMDA-evoked responses in AII and A17 1147 
amacrine cells. A: top, time series of peak response amplitude of an AII amacrine cell 1148 
(Vhold = -60 mV) to repeated application of NMDA (1 mM, 1 s duration) at intervals of 1149 
60 s, first in normal extracellular solution ([Ca2+]o = 2.5 mM), followed by nominally 1150 
Ca2+-free extracellular solution (continuous line), and return to normal extracellular 1151 
solution. Notice response increase in Ca2+-free solution. Numbers (1, 2, and 3) 1152 
correspond to raw data traces (bottom) displaying responses evoked by NMDA 1153 
application in normal (1, 3) and Ca2+-free (2) bath solution. B: peak amplitude of 1154 
NMDA-evoked responses in AII amacrine cells (n = 5 cells) in control solution with 1155 
[Ca2+]o = 2.5 mM (Control; left bar), in nominally Ca2+-free extracellular solution 1156 
([Ca2+]o = 0; middle bar), and after return to control solution with [Ca2+]o = 2.5 mM 1157 
(Recovery; right bar). C: top, time series of peak response amplitude of an A17 1158 
amacrine cell (Vhold = -60 mV) to repeated application of NMDA (1 mM, 1 s duration) 1159 
at intervals of 60 s, first in normal extracellular solution ([Ca2+]o = 2.5 mM), followed 1160 
by nominally Ca2+-free extracellular solution (continuous line), and return to normal 1161 
extracellular solution. Notice response increase in Ca2+-free solution. Numbers (1, 2, 1162 
and 3) correspond to raw data traces (bottom) displaying responses evoked by 1163 
NMDA application in normal (1, 3) and Ca2+-free (2) bath solution. D: peak 1164 
amplitude of NMDA-evoked responses in A17 amacrine cells (n = 5 cells) in control 1165 
solution with [Ca2+]o = 2.5 mM (Control; left bar), in nominally Ca2+-free extracellular 1166 
solution ([Ca2+]o = 0; middle bar), and after return to control solution with [Ca2+]o = 2.5 1167 
mM (Recovery; right bar). 1168 
